Voyager Therapeutics (VYGR) Cash from Operations (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Cash from Operations data on file, last reported at 33419000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 11.81% year-over-year to 33419000.0; the trailing twelve-month figure through Mar 2026 stood at 127991000.0 (down 14.31% YoY), and the FY2025 full-year result was 132467000.0, down 765.23% from the prior year.
• Cash from Operations slipped to 33419000.0 in Q1 2026, from 30263000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 123565000.0 in Q1 2023 to a low of 37895000.0 in Q1 2025.
• A 5-year average of 6810941.18 and a median of 21051000.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations jumped 261.67% in 2022 and sank 3682.04% in 2024, its largest moves.
• Tracing VYGR's Cash from Operations over 5 years: stood at 12244000.0 in 2022, then slumped by 94.05% to 23760000.0 in 2023, then soared by 38.85% to 14529000.0 in 2024, then tumbled by 108.29% to 30263000.0 in 2025, then dropped by 10.43% to 33419000.0 in 2026.
• Business Quant data shows VYGR's Cash from Operations at 33419000.0 in Q1 2026, 30263000.0 in Q4 2025, and 31048000.0 in Q3 2025.